In the Article titled, “GlaxoSmithKline to drop sales targets as basis for incentive pay” it states that “GlaxoSmithKline P.L.C. just announced that it will no longer base bonuses of many of its 5,500-member sales staff on their individual sales targets. So how will the drug company, which employs thousands in the region, evaluate the performance of its sales reps?” The company is planning on basing sales representative pay on, “customer feedback, in part, will determine bonuses as well as a sales rep’s “adherence to company values of transparency, integrity, respect and patient-focus.”
While I was reading the article my first thought was that it seems like a pretty big shift in sales compensation strategy and by the end I had a few questions that the article didn’t address that I wanted answered – Is this a prevailing trend, could the idea of softer measures be applied to other industries and is it even feasible as a way to motivate and change behavior?
To get some answers to my questions I turned to my colleague Scott Barton. Scott is a managing principal of NewSigma, a professional services firm dedicated to helping companies align their sales compensation plans with transformative sales strategies.
Justin Lane (JL): Is the change referenced cyclical or part of an overall transformation?
Scott Barton (SB): “Large pharmaceutical companies like GSK are transforming their sales organizations in response to a number of market trends, including consolidation of drug companies and buying groups, increased regulation and a significant increase in marketing spend to stimulate more pull-through, initiated by the patient or physician, in the sales channel.”
JL: Is this transformation unique? Has it played out in other industries?
SB: “Certainly. We’ve seen this transformation in a lot of technology sectors, where an emphasis on marketing, product development and alternative sales channels decreased the prominence of the direct sales representative.”
JL: So the article points out this shift will have implications for how the company pays its salespeople. Do you agree with its premise?
SB: “I would expect management to put less emphasis on variable pay and recognition programs, more on relationship sales skills and base salary, which compensates for skill.”
“However, the company is short sided to initiate this shift through a significant change to its sales compensation program. While the plan should make a statement about what behaviors management expects from its salespeople, compensation is not a surrogate for sales strategy and a performance management system.”
“To suggest the company will offer less variable pay for high performers while it tries to figure out how to measure performance is certain to alienate the people who can help deliver on the company’s new strategy.”
JL: Maybe the company needs a different type of salesperson?
SB: “Could be. In some cases, salespeople who help fledgling startups become multi-billion dollar behemoths are not well suited for a relatively mature, multi-channel sales strategy. These people ride waves of product innovation and high growth. Once that wave crests, they’re paddling out for the next one.”
Note these wave-riding sharks are the exception, not the norm. Most sales professionals adapt to maturing markets and more-complex sales models.
You mean they willingly forgo lucrative upside pay opportunity?
SB: “Not without some resistance. I didn’t willingly give up my sports car to make room for a minivan. The minivan was part of an overall transformation in my personal life. And the sports car presented a level of risk I didn’t think was appropriate for this new role in my life. It’s all about tradeoffs.”
JL: Trading off a set of wheels is different from a reduction in pay, isn’t it?
SB: “My point is salespeople must understand the big picture and the playbook to determine if the change is right for them. This includes how management measures success and defines successful outcomes. Salespeople, unlike many other functional roles, have a strong financial orientation and need a strong line of sight between their contributions and their business unit’s financial goals.”
Can a measure like customer satisfaction adequately substitute a salesperson’s financial goal?
SB: “Physician satisfaction with a sales rep, referenced in the article as potential measure of sales success, does not necessarily secure buyer loyalty, market share and profitable growth for the drug company. The problem with these types of qualitative measures is they tend to produce sales rep pay amounts that aren’t aligned with the company’s financial performance.”
JL: So how can a company like GSK help ensure a successful transformation?
SB: “Management has to engage its salespeople in the strategy and motivate them to help drive that strategy forward. Starting the discussion with compensation seems intuitive but is too emotional a topic to motivate a thoughtful response.”
“Success outcomes I’ve observed follow a basic storyline: what’s changing; why is it good for the sales rep; what does success look like and what does each rep need to do to be successful? If the story’s first chapter is about the company’s intent to reduce compensation, management should not expect to engage the sales force. The result is distracted salespeople, loss of sales talent and reduced productivity.”
Thanks Scott! As usual great insights from Mr. Barton! If you would like to read more of his musings and expert knowledge about sales compensation please visit the very articulate blog www.salescompinsights.com His contact information and some information about his company are below:
Scott Barton
NewSigma, LLC specializes in sales compensation planning and operations. NewSigma consultants work with companies to design and implement solutions to increase sales productivity and reduce operational expense.